Physicians' gender is associated with risk factor control in patients on antihypertensive and lipid lowering treatment

被引:22
|
作者
Journath, Gunilla [1 ,2 ]
Hellenius, Mai-Lis
Carlsson, Axel C. [3 ,4 ]
Wandell, Per E. [3 ]
Nilsson, Peter M. [5 ]
机构
[1] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Karolinska Univ Hosp, S-17176 Stockholm, Sweden
[2] Merck Sharp & Dohme Sweden AB, Sollentuna, Sweden
[3] Karolinska Inst, Ctr Family & Community Med, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden
[4] Karolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, S-17176 Stockholm, Sweden
[5] Lund Univ, Univ Hosp, Dept Clin Sci, Malmo, Sweden
关键词
Cholesterol; gender; hypertension; risk factors; BLOOD-PRESSURE CONTROL; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; HYPERTENSIVE PATIENTS; SEX-DIFFERENCES; HEART-DISEASE; WOMEN; CARE; PREVENTION; ADHERENCE;
D O I
10.3109/08037051003768247
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The objective was to study gender differences in cardiovascular risk factors, lipid and blood pressure control in patients on combined lipid-lowering and antihypertensive treatment, in relation to gender of their physician. This was a cross-sectional study of 4319 patients (53% men) on lipid-lowering and antihypertensive treatment from two national surveys. Male physicians included 1643 men and 1311 women, and female physicians 605 men and 648 women. All data were collected consecutively from medical records. Women were older, had a higher systolic blood pressure (SBP), pulse pressure (PP), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), SBP >= 140 mmHg, and more often isolated systolic hypertension (ISH) compared with men. Men compared with women had more often diabetes, higher cardiovascular risk (SCORE) and achieved treatment goals more often for blood pressure in non-diabetics and TC in both non-diabetics and diabetics. Both men and women in well controlled and intermediate controlled groups were more often treated by physicians of their own gender. The female diabetes patients treated by female primary healthcare physicians more often achieved treatment goals for blood pressure [SBP/diastolic blood pressure (DBP) <130/80 mmHg]. Female physicians' male patients with diabetes more often belonged to the well controlled group. Physicians' gender may influence the control of risk factors for cardiovascular disease in both men and women on combined antihypertensive and lipid-lowering therapy.
引用
收藏
页码:240 / 248
页数:9
相关论文
共 50 条
  • [21] Diminishing Efficacy of Combination Therapy, Response-Heterogeneity, and Treatment Intolerance Limit the Attainability of Tight Risk Factor Control in Patients with Diabetes
    Timbie, Justin W.
    Hayward, Rodney A.
    Vijan, Sandeep
    HEALTH SERVICES RESEARCH, 2010, 45 (02) : 437 - 456
  • [22] Antihypertensive drug class in combination with lipid lowering treatment for primary prevention of cardiovascular disease in the elderly
    Zhou, Zhen
    Chowdhury, Enayet K.
    Breslin, Monique
    Curtis, Andrea J.
    Reid, Christopher M.
    Nelson, Mark
    HEART & LUNG, 2022, 51 : 40 - 45
  • [23] Lipid-lowering treatment in patients at high cardiovascular risk discharged from an Italian hospital
    Spighi, Alessandro
    Tartagni, Elisa
    D'Addato, Sergio
    Dormi, Ada
    Borghi, Claudio
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2013, 14 (04) : 270 - 275
  • [24] Baseline Quality of Life and Risk of Stroke in the Antihypertensive and Lipid Lowering to Prevent Heart Attack (ALLHAT) Trial
    Shams, Tanzila
    Auchus, Alexander P.
    Oparil, Suzanne
    Wright, Clinton
    Wright, Jackson
    Furlan, Anthony J.
    Sila, Cathy A.
    Davis, Barry
    Pressel, Sara
    Yamal, Jose-Miguel
    Einhorn, Paula
    Cutler, Jeff
    Lerner, Alan J.
    STROKE, 2015, 46
  • [25] The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology
    De Smedt, Delphine
    De Bacquer, Dirk
    De Sutter, Johan
    Dallongeville, Jean
    Gevaert, Sofie
    De Backer, Guy
    Bruthans, Jan
    Kotseva, Kornelia
    Reiner, Zeljko
    Tokgozoglu, Lale
    Clays, Els
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 209 : 284 - 290
  • [26] The relationship between changes in health behaviour and initiation of lipid-lowering and antihypertensive medications in individuals at high risk of ischaemic heart disease
    Hempler, Nana Folmann
    Krasnik, Allan
    Pisinger, Charlotta
    Jorgensen, Torben
    BMC PUBLIC HEALTH, 2012, 12
  • [27] The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    Juraschek, Stephen P.
    Simpson, Lara M.
    Davis, Barry R.
    Shmerling, Robert H.
    Beach, Jennifer L.
    Ishak, Anthony
    Mukamal, Kenneth J.
    JOURNAL OF HYPERTENSION, 2020, 38 (05) : 954 - 960
  • [28] Global Cardiovascular Risk Associated With Hypertension and Extent of Treatment and Control According to Risk Group
    Wong, Nathan D.
    Dede, Jennifer
    Chow, Vincent H.
    Wong, Ken S.
    Franklin, Stanley S.
    AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (05) : 561 - 567
  • [29] Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
    Ferrannini, Giulia
    De Bacquer, Dirk
    Vynckier, Pieter
    De Backer, Guy
    Gyberg, Viveca
    Kotseva, Kornelia
    Mellbin, Linda
    Norhammar, Anna
    Tuomilehto, Jaakko
    Wood, David
    Ryden, Lars
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [30] The Importance of Antihypertensive and Lipid-Lowering Therapy in the Treatment of Patients with a New Coronavirus Infection COVID-19
    Podzolkov, V., I
    Tarzimanova, A., I
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2021, 17 (02) : 310 - 314